– USA, MA – Catamaran Bio, Inc., a biotechnology company developing off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies to treat cancer, today announced the appointment of Frank Lee as Chair of its Board of Directors.
Mr. Lee has over 25 years of global experience in biopharmaceutical product development and commercial leadership across a wide range of therapeutic areas, including solid tumor oncology.
“We are pleased to welcome Frank as Chair of our Board. Frank has an impressive track record of leadership in biopharmaceutical organizations at growth stages, including new product launches. His extensive experience advancing breakthrough treatments in cancer markets will be invaluable to Catamaran as we advance our pipeline of off-the-shelf CAR-NK cell therapies to bring a new class of cell therapies to patients,” said CEO, Dr. Alvin Shih.
About Frank Lee
Frank Lee is CEO of Forma Therapeutics and has more than 25 years of global experience in product development and commercial leadership across a wide range of therapeutic areas. He served as SVP, global product strategy, and therapeutic area head for the immunology, ophthalmology, and infectious diseases at Genentech. At Genentech, he also served as VP of the HER2/Breast Cancer Franchise, which included Herceptin, Perjeta, and Kadcyla. As VP of oral oncolytic, Mr. Lee held P&L responsibility for Tarceva, Zelboraf, Erivedge, and Xeloda. Before joining Genentech, he spent approximately thirteen years at Novartis, Janssen, and Eli Lilly in various engineering, manufacturing, sales and marketing, and business development roles.
“I am honored to serve as Chair of Catamaran’s Board and look forward to working with an impressive team to help advance Catamaran’s allogeneic CAR-NK cell therapies toward the clinic. This is a very exciting time in the cell therapy field, and I’m eager to share my expertise to support Catamaran’s mission to realize the full potential of CAR-NK cell therapies to provide new treatment options for cancer patients,” commented Frank Lee. “
He holds a BS in chemical engineering from Vanderbilt University and an MBA from the Wharton Graduate School of Business. Mr. Lee also serves on the board of directors of Bolt Biotherapeutics Inc.
About Catamaran Bio
Catamaran Bio is developing novel, off-the-shelf chimeric antigen receptor (CAR)-NK cell therapies designed to treat a broad range of cancers, including solid tumors. Our proprietary capabilities enable us to harness the natural cancer-fighting properties of NK cells and enhance and tailor their effectiveness with the power of synthetic biology and innovative non-viral cell engineering. We are using our TAILWIND platform, an integrated suite of technologies, to specifically address the end-to-end methods of engineering, processing, and manufacturing NK cells and rapidly advance our pipeline of CAR-NK cell therapy programs. Our team combines experienced biopharmaceutical leadership with founding scientists who are pioneers in NK cell biology, engineering, manufacturing, and clinical application. Catamaran is backed by leading financial and corporate investors, including SV Health Investors, Sofinnova Partners, Lightstone Ventures, Takeda Ventures, Astellas Venture Management, and the UMN Discovery Capital investment program.
For more information: https://catamaranbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.